{"transactions":[{"id":156514,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12427,"kind":"organization","name":"Merck Sharp & Dohme Research GmbH","position":3,"cik":"0001665244","reported_name":"Merck Sharp & Dohme Research GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Shares","published_at":"2016-02-10T21:28:20.000Z","date":"2016-02-08","kind":"exercise","acquired":false,"shares":5128205,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary, MSDRG"},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A-2 Preferred Shares (the \"Series A-2 Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A-2 Preferred Shares (the \"Series A-2 Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5128205},"source":{"system":"sec-edgar","filing":"0001635698-16-000062","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/310158/000163569816000062/form4.xml","form_type":"4"}},{"id":156513,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12427,"kind":"organization","name":"Merck Sharp & Dohme Research GmbH","position":3,"cik":"0001665244","reported_name":"Merck Sharp & Dohme Research GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Shares","published_at":"2016-02-10T21:28:20.000Z","date":"2016-02-08","kind":"exercise","acquired":false,"shares":18518519,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary, MSDRG"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18518519},"source":{"system":"sec-edgar","filing":"0001635698-16-000062","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/310158/000163569816000062/form4.xml","form_type":"4"}},{"id":156512,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12427,"kind":"organization","name":"Merck Sharp & Dohme Research GmbH","position":3,"cik":"0001665244","reported_name":"Merck Sharp & Dohme Research GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2016-02-10T21:28:20.000Z","date":"2016-02-08","kind":"other","acquired":true,"shares":7942314,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary, MSDRG"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The 7,942,314 Ordinary Shares were issued to MSDRG in exchange for the cancellation of MSDRG's promissory note plus accrued and unpaid interest thereon (together, $14,693,281)(the \"Note Exchange Amount\") upon the closing of the initial public offering of the Issuer. The number of shares issued was determined by dividing the Note Exchange Amount by the initial public offering share price of $1.85."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The 7,942,314 Ordinary Shares were issued to MSDRG in exchange for the cancellation of MSDRG's promissory note plus accrued and unpaid interest thereon (together, $14,693,281)(the \"Note Exchange Amount\") upon the closing of the initial public offering of the Issuer. The number of shares issued was determined by dividing the Note Exchange Amount by the initial public offering share price of $1.85."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":7942314,"source":{"system":"sec-edgar","filing":"0001635698-16-000062","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/310158/000163569816000062/form4.xml","form_type":"4"}},{"id":156511,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12427,"kind":"organization","name":"Merck Sharp & Dohme Research GmbH","position":3,"cik":"0001665244","reported_name":"Merck Sharp & Dohme Research GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2016-02-10T21:28:20.000Z","date":"2016-02-08","kind":"exercise","acquired":true,"shares":5128205,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary, MSDRG"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series A-2 Preferred Shares (the \"Series A-2 Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A-2 Shares did not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":5128205,"source":{"system":"sec-edgar","filing":"0001635698-16-000062","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/310158/000163569816000062/form4.xml","form_type":"4"}},{"id":156510,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2807,"kind":"organization","name":"Merck & Co., Inc.","position":1,"cik":"0000310158","reported_name":"Merck & Co., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11928,"kind":"organization","name":"Merck Sharp & Dohme Corp.","position":2,"cik":"0000942443","reported_name":"Merck Sharp & Dohme Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12427,"kind":"organization","name":"Merck Sharp & Dohme Research GmbH","position":3,"cik":"0001665244","reported_name":"Merck Sharp & Dohme Research GmbH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2016-02-10T21:28:20.000Z","date":"2016-02-08","kind":"exercise","acquired":true,"shares":18518519,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary, MSDRG"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Shares (the \"Series A Shares\") of the Issuer automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon the closing of the initial public offering of the Issuer on February 8, 2016. The Series A Shares did not have an expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Series A Preferred Shares and Series A-2 Preferred Shares were, and the Ordinary Shares received from the conversion thereof are, owned directly by Merck Sharp & Dohme Research GmbH (\"MSDRG\"), which is a wholly owned subsidiary of Merck Sharp & Dohme Corp. (\"MSD\"), which is a wholly owned subsidiary of Merck & Co., Inc. (\"Merck\"). MSD and Merck are indirect beneficial owners of the reported securities."}],"balance_after":18518519,"source":{"system":"sec-edgar","filing":"0001635698-16-000062","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/310158/000163569816000062/form4.xml","form_type":"4"}}]}